Business & Finance

Reuters exclusively reports J&J CEO pay irks investors upset with opioid lawsuits fallout

Reuters exclusively reported that Johnson & Johnson is coming under fire from some investors who are raising questions about companies that give their chief executives hefty pay raises despite facing billions of dollars in legal costs over their role in the U.S. opioid crisis. The Investors for Opioid & Pharmaceutical Accountability (IOPA), wrote to J&J’s board in January asking them to review their pay practices in light of the opioid litigation and agreed-to settlements, said Donna Meyer, director of shareholder advocacy at Mercy Investment Services Inc. to Reuters. 

Article Tags
Topics of Interest: Business & Finance
Type: Reuters Best
Sectors: Equities
Regions: North America
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Sign up for email updates